Virbac: 2025 annual results

Summary by AI BETAClose X

Virbac reported robust 2025 results with organic revenue growth of 7.9% at constant exchange rates and scope, reaching €1,464.7 million, and an adjusted EBIT margin of 16.3%. Consolidated net income increased by 3.2% to €150.5 million, supported by strong cash generation of €93 million which funded the Thyronorm acquisition, keeping net debt relatively stable at €172.8 million. For 2026, the company anticipates revenue growth between 5.5% and 7.5% at constant rates and scope, with an adjusted recurring operating income margin around 17%.

Disclaimer*

Companies

Virbac SA (0NM7)
UK 100

Latest directors dealings